PSMD14 played a vital role in initiation and progression of hepatocellular carcinoma(HCC).However,PSMD14 and its-related genes for the immune prognostic implications of HCC patients have rarely been analyzed.Messenger...PSMD14 played a vital role in initiation and progression of hepatocellular carcinoma(HCC).However,PSMD14 and its-related genes for the immune prognostic implications of HCC patients have rarely been analyzed.Messenger RNA expression profiles and clinicopathological data were downloaded from The Cancer Genome Atlas(TCGA)and International Cancer Genome Consortium(ICGC)database-Liver Hepatocellular Carcinoma(LIHC).Additionally,we used multi-dimensional bioinformatics analysis to construct and validate a PSMD14-based immune prognostic signature(including RBM45,PSMD1,OLA1,CCT6A,LCAT and IVD)for HCC prognosis prediction.Patients in the high-risk group shown significantly poorer survival than patients in the low-risk group.Calibration curves confirmed the good consistency between the clinical nomogram prediction and the actual observation.Gene set enrichment analyses(GSEA)revealed several significantly enriched pathways,which might help explain the underlying mechanisms.Besides,the rt-PCR further validates the expression of seven immune genes in HCC cells.Our study identified a novel PSMD14-based signature for HCC prognosis prediction,it provided new potential prognostic biomarkers and therapeutic targets for immunotherapy of HCC.展开更多
基金the National Natural Science Foundation of China(81772995 and 81472266)the Excellent Youth Foundation of Jiangsu Province,China(BK20140032)Jiangsu Province’s Key Provincial Talents Program(ZDRCA2016090).
文摘PSMD14 played a vital role in initiation and progression of hepatocellular carcinoma(HCC).However,PSMD14 and its-related genes for the immune prognostic implications of HCC patients have rarely been analyzed.Messenger RNA expression profiles and clinicopathological data were downloaded from The Cancer Genome Atlas(TCGA)and International Cancer Genome Consortium(ICGC)database-Liver Hepatocellular Carcinoma(LIHC).Additionally,we used multi-dimensional bioinformatics analysis to construct and validate a PSMD14-based immune prognostic signature(including RBM45,PSMD1,OLA1,CCT6A,LCAT and IVD)for HCC prognosis prediction.Patients in the high-risk group shown significantly poorer survival than patients in the low-risk group.Calibration curves confirmed the good consistency between the clinical nomogram prediction and the actual observation.Gene set enrichment analyses(GSEA)revealed several significantly enriched pathways,which might help explain the underlying mechanisms.Besides,the rt-PCR further validates the expression of seven immune genes in HCC cells.Our study identified a novel PSMD14-based signature for HCC prognosis prediction,it provided new potential prognostic biomarkers and therapeutic targets for immunotherapy of HCC.
